Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: ADMD

8-2-16 SmallCapVoice Interview with Advanced Medical Isotope Corp. (ADMD)

Advanced Medical Isotope Corp. (ADMD)

CEO and Chairman James C. Katzaroff and Dr. Darrell Fisher of Advanced Medical Isotope Corporation (or “AMI”) (ADMD), a late stage radiation oncology focused medical device company, called in to SmallCapVoice.com, Inc. to discuss their advances with their RadioGel (TM) product and the future plans for the product. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

This interview may …

Continue Reading

Posted in Interviews| Tagged |

4-26-16 SmallCapVoice Interview with Advanced Medical Isotope Corporation (ADMD)

Advanced Medical Isotope Corporation (ADMD)

AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Albert Denittis both called in to SmallCapVoice.com, Inc. to discuss the applications, benefits and markets for the Y-90 RadioGel(TM) device. The Y-90 RadioGel(TM) device is one of several Y-90 brachytherapy products in development by AMI that may provide a safer, quicker and less expensive treatment to certain cancers including tumors deemed inoperable. Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The …

Continue Reading

Posted in Interviews| Tagged |

4-11-16 SmallCapVoice Interview with Advanced Medical Isotope Corporation (ADMD)

Advanced Medical Isotope Corporation (ADMD)

AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Alice Villalobos, DVM, FNAP, Company chairperson of AMI’s new Veterinary Medicine Advisory Board called in to SmallCapVoice.com, Inc. to go over the exciting new markets and news for the Company. Recently ADMD announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource …

Continue Reading

Posted in Interviews| Tagged |

Advanced Medical Isotope Corporation Provides Progress Report on FDA Pre-Market Notification Application

KENNEWICK, Wash., Feb. 21, 2014 /PRNewswire/ — Advanced Medical Isotope Corporation (“AMIC”) (OTCBB: ADMD), a company engaged in the development, production and distribution of medical isotopes focused on yttrium-90 brachytherapy devices, today announced that it has received a response from the FDA to its pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 (Y-90) RadioGel(tm) patented brachytherapy cancer product.

(Logo: http://photos.prnewswire.com/prnh/20140115/CL46762LOGO )

The FDA, which previously advised AMIC that it would review the product as a medical device, has further advised AMIC that it has determined that the product is classified by statute as a Class III medical device, unless the device is reclassified. The Company intends to work with the FDA to seek such reclassification, unless the additional steps required for approval of this product as a Class III medical device are more efficient. The Company has …

Continue Reading

Posted in Client News| Tagged |

Advanced Medical Isotope Corporation Announces that it will present at “TEN;” Noble Financial Capital Markets’ Tenth Annual Equity Conference on January 22

KENNEWICK, Wash., Jan. 15, 2014 /PRNewswire/ — Advanced Medical Isotope Corporation (“AMIC”) (OTCBB: ADMD), a company engaged in the development, production and distribution of medical isotopes focused on yttrium-90 brachytherapy devices, today announced that its CEO, James C. Katzaroff, will present AMIC’s corporate overview at “TEN;” Noble Financial Capital Markets’ Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday, January 22, 2014 at 8:30am Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20140115/CL46762LOGO)

AMIC intends to transition to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, yttrium-90 RadioGel(TM). The Company then will seek to commercialize its innovative in vivo delivery systems in the United States and to seek analogous regulatory approvals outside of the United States, including CE certification in the European Economic Area.

AMIC operates a linear accelerator in Washington used to manufacture FDG for sale to local hospitals and distributes nuclear isotopes and …

Continue Reading

Posted in Client News| Tagged |

Advanced Medical Isotope Corporation Announces Three Year Business Strategy Focused on Transitioning From a Development-Stage Company to an Operating Company

Operations to Center on Yttrium-90 Brachytherapy Products Following Anticipated Receipt of FDA Clearance of Y-90 RadioGel(TM) Brachytherapy Device

KENNEWICK, Wash., Dec. 2, 2013 (GLOBE NEWSWIRE) — Advanced Medical Isotope Corporation (“AMIC”) (ADMD), a company engaged in the development, production and distribution of medical isotopes, today announced that its Board of Directors has approved a three year business strategy focused on transitioning to full operations in 2014, following the anticipated receipt of FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel(TM).

The business strategy results from the Company’s success in developing a family of three brachytherapy devices and the Company’s belief that there is: (1) strong market potential for these products in the United States and internationally, (2) the potential for attractive operating margins from the commercialization of such devices, (3) a considerably smaller capital requirement to complete the regulatory process and deploy these devices, as compared to the capital …

Continue Reading

Posted in Client News| Tagged |